Business Context and Reporting Period
Company: Zhengye Biotechnology Holding Limited (a Cayman Islands exempted company)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended June 30, 2025
Filing Date: December 12, 2025
Principal Executive Office: No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin City, Jilin Province, China
Key Financial Metrics
The provided filing text serves as a cover page and index. It references the attachment of unaudited consolidated financial statements (Exhibit 99.1) and Management's Discussion and Analysis (Exhibit 99.2) but does not contain the specific numerical data within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific data to compare the current period against the prior comparable period. Material changes are expected to be detailed in the attached Exhibit 99.2 (MD&A).
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. These disclosures are located in the attached exhibits referenced in the filing.
Investor Verification Checklist
- Review Exhibit 99.1 for the actual unaudited consolidated financial statements to verify revenue, net income, and cash flow figures.
- Examine Exhibit 99.2 for Management's Discussion and Analysis to understand operational performance and material changes.
- Confirm the status of the company's Form 20-F annual reporting cycle as indicated by the checkmark in the filing.
- Verify the accuracy of the Inline XBRL data (Exhibits 101) against the narrative financial statements.